(Information sent by the signatory company)

– AtomVie Global Radiopharma Inc. builds industry-leading radiopharmaceutical CDMO facility in Hamilton, Ontario

TORONTO, March 1, 2023 /PRNewswire/ — AtomVie Global Radiopharma Inc. ( AtomVie) is pleased to announce the execution of a lease with Panattoni Development Company in Hamilton, Ontario, Canada for their new state-of-the-art facility. AtomVie’s new facility will be dedicated to the global manufacturing and distribution of high-volume commercial and clinical GMP-compliant radiotherapeutic products, a fast-growing and innovative class of drugs for the treatment of cancer patients.

Currently located on the campus of McMaster University, AtomVie successfully operates a world-leading Contract Development and Manufacturing Organization (CDMO) facility that hosts over 10 international radiopharmaceutical GMP manufacturing programs. The new 64,000 square foot facility, which is expected to become operational in 2024, will increase production capacity by more than 10 times, allowing for the expansion of its clinical and commercial operations to meet the needs of the rapidly expanding radiopharmaceutical market. .

Hallmarks of the new plant include clean rooms and laboratories to maintain more than 18 production lines and space for dedicated high-volume commercial manufacturing. The facility is strategically located near Toronto Pearson International Airport, John C. Munro Hamilton International Airport, and the US border. AtomVie is well positioned to consolidate and grow its presence as the world’s leading GMP manufacturing of radiopharmaceuticals, Serving patients locally and globally.

“AtomVie celebrates another milestone by beginning construction that will increase our capacity more than tenfold,” said Bruno Paquin, CEO of AtomVie Global Radiopharma. “We are delighted to continue to be a part of Hamilton’s radiopharmaceutical ecosystem, and by partnering with Panattoni, we were able to choose the home of our new facility to meet clinical and commercial supply needs for radiotherapeutics, resulting in patients receiving the therapies that they so badly needed.”

Kevin McNeill, Partner at Avego and Chairman of the Board of Directors of AtomVie, added: “AtomVie’s new facility will provide much-needed capacity to the high-growth global radiopharmaceutical market. We are pleased to be able to meet the growing needs of our customers and patients. “.

About AtomVie Global Radiopharma Inc.

AtomVie, officially launched in August 2022 with the successful closing of its $40 million Series A financing from Avego. AtomVie, a spin-out of the Center for Probe Development and Commercialization (CPDC), is a world leading CDMO for GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals. Building on experience developed at CPDC, a McMaster University Center of Excellence, and its reputation as a high-quality radiopharmaceutical CDMO, AtomVie offers the full range of combined scientific, technical, regulatory, quality, logistics, and commercial expertise. with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial market. AtomVie currently serves 10 international clients conducting studies in more than 17 countries around the world.

For more information about AtomVie, visit www.atomvie.com or contact: info@atomvie.com.

Photo – https://mma.prnewswire.com/media/2012147…Logo – https://mma.prnewswire.com/media/2012148…

View original content: https://www.prnewswire.com/news-releases/atomvie-global-radiopharma-inc-construye-una-planta-cdmo-radiofarmaceutica-en-ontario-301759448.html